Aleafia Health Begins Trading on the TSX Big Board Exchange: Aleafia Health Inc. (TSX: ALEF) (OTCQX: ALEAF) (FRA: ARAH) is pleased to confirm that the Company’s common shares have commenced trading today on the Toronto Stock Exchange (“TSX”). Our common shares continue to trade under the symbol “ALEF.” Upon listing on TSX, Aleafia Health will also become a reporting issuer in the Province of Ontario.
Listed Emblem Warrants
All previously listed common share purchase warrants of Emblem Corp. (“Emblem”) remain listed on the TSX Venture Exchange (“TSXV”) under their existing trading symbols and are now exercisable each at the original exercise price into 0.8377 of a common share of Aleafia Health. The three classes of Emblem warrants that remain posted for trading on the TSXV are as follows:
MedMen and Gotham Green Partners Agree to Terms on $250 Million Investment: MedMen Enterprises Inc.(CSE: MMEN) (OTCQX: MMNFF) (FSE: A2JM6N), is pleased to announce that it has signed a binding term sheet for a senior secured convertible credit facility of up to US$250,000,000 from funds managed by Gotham Green Partners, an investor in the global cannabis industry. Management believes this is the largest investment to date by a single investor in a publicly traded cannabis company with U.S. operations.
“This strategic partnership with Gotham Green Partners represents another key milestone for MedMen and stems from our long-standing relationship with The Cronos Group and GGP’s brand portfolio,” said Adam Bierman, CEO of MedMen. “The growth capital will be used to operationalize the balance of our footprint and we look forward to creating further alignment with GGP and their global cannabis platform.”
Canopy Growth Acquires AgriNextUSA, Hemp Pioneer to Join Company as Strategic Advisor: Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) is pleased to announce today it has acquired AgriNextUSA, a hemp enterprise led by CEO Geoff Whaling, that has been at the forefront of hemp advocacy and building a vibrant hemp sector in the USA. The acquisition will accelerate Canopy Growth’s entry into key American jurisdictions as regulations surrounding the full use of hemp as a crop begin to be implemented, thanks in part to the recently enacted 2018 US Farm Bill.
- Hemp pioneer Geoff Whaling to join Canopy Growth USA as Strategic Advisor.
- Hemp and CBD in addition to being the co-Founder and President of Hemp Developments LLC.
“The United States is the next stop on Canopy Growth’s desired path to becoming a leading, revenue-generating company focused on all aspects of cannabinoids and their potential,” said Bruce Linton, co-CEO and Chairman of Canopy Growth. “Our significant investments, acquisitions and compilation of talented leaders such as Geoff will position us for swift expansion throughout the United States. By collaborating with a pioneer like Geoff, who has been involved with our team since our earliest days in 2013, we will aim to turn hemp supplied by American farmers into a wide range of products.”
TransCanna Signs Definitive Closing Documents to Acquire 196,000 Sq Ft Cannabis Facility: TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) is pleased to announce that the Company has signed definitive closing documents to acquire the land, building and asset package which includes an existing 196,000 square foot facility on 5.5 acres of land as well as cannabis packaging and processing equipment. As referenced in the Company’s February 4th, 2019 press release, the facility has undergone major renovations over the past twenty-four months which has created specific divisions for nursery, cultivation, manufacturing, extracting, bottling, remediation, and transportation & distribution. The total cost for the renovations was US$8 million.
“Acquiring arguably the largest vertically integrated cannabis centric three-storey multi-purpose facility in California reinforces our strategy to be fully self-contained in our ecosystem. We also have an additional 5 acres in the green zone adjacent to the facility to build up to 600,000 sq. ft. three-storey grow facility to supply our own biomass for the brands we acquire or create,” stated Jim Pakulis, CEO of TCAN.
Aleafia Health Announces Results of Medical Cannabis Study Focused on Epileptic Patients: Aleafia Health Inc. (TSXV: ALEF) (OTCQX: ALEAF) (FRA: ARAH) (“Aleafia Health” or the “Company”), announced the results of a 4,000 medical cannabis patient study (“The Study”) examining changes in employment and disability status among medical cannabis patients. The study was published on March 13, 2019 in the peer-reviewed Journal of Drug Issues, and is, to the Company and author’s knowledge, the first to ever directly observe physician-led medical cannabis usage and labour force status over time.
- First of its Kind Study Written by Dr. Andrew Davis and Published in Peer-Reviewed “Journal of Drug Issues”.
- 4000 Medical Cannabis Patient Study Leveraged Aleafia Health’s Proprietary Medical Cannabis Database.
“Aleafia Health continues to treat a high volume of patients suffering from epilepsy and the results of this study further cement the conclusion that many of our physicians have already made regarding the effectiveness of medical professional cannabis care,” said Aleafia Health Chief Medical Officer Dr. Michael Verbora. “We will continue to leverage our IP and leading cannabis data to further advance patient care through advanced treatment methods and specialized product development.”
Supreme Cannabis Set to Launch Adult-Use Cannabis Oil Products in April: The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that the Company expects its previously announced oil products line to be introduced to adult-use consumers in select Canadian markets starting April 2019.
- Proprietary oil formulation expected to be introduced in April 2019 for select markets with roll out to additional provinces expected by the end of June 2019.
- The oil products will be produced using High-End CannabisTM grown by 7ACRES and formulated to preserve the naturally occurring terpenes unique to the strain.
“Premium oils require premium cannabis,” said Navdeep Dhaliwal, CEO of Supreme Cannabis. “Our formulation will leverage super-critical CO2 technology to produce a high quality, purified cannabis oil which we re-formulate with the naturally occurring cannabis terpenes from our 7ACRES’ High-End CannabisTM. The result is a unique, plant-based cannabis oil that carries the award-winning qualities of our flower into an oil product for consumers looking for a premium cannabis oil experience.”
iAnthus Closes $35 Million Private Placement, Company Set to Expand 11-State Footprint: iAnthus Capital Holdings, Inc. (CSE: IAN) (OTCQX: ITHUF), which owns, operates, and partners with best-in-class regulated cannabis operations across the United States, is pleased to announce that it has completed the private placement offering of US$35 million of unsecured convertible notes and corresponding warrants to three investors (the “Offering”). The proceeds from the Offering will be applied to continue the build-out of facilities across the Company’s 11-state footprint.
“With the closing of the transaction with MPX Bioceutical Corporation in early February, iAnthus remains driven to become a market leader across our 11-state platform. This financing allows the Company to simultaneously strengthen our balance sheet, deepen our investor base, and fund our growth capital,” said Hadley Ford, CEO of iAnthus.
Tilray Reports Full Year 2018 Financial Results, Q4 Revenue Soars 204% to $15.5 Million: Tilray, Inc., (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today reported financial results for the fourth quarter and year ended December 31, 2018. All financial information in this press release is reported in U.S. dollars unless otherwise indicated.
“2018 was a very successful year for Tilray with many corporate milestones. Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,” commented Brendan Kennedy, President and Chief Executive Officer of Tilray. “Looking ahead, we remain committed to pursuing global growth opportunities and will be disciplined in deploying capital, particularly in the United States and Europe, where we believe we have multiple paths for value creation.”
Canopy Growth and DNA Genetics Extend Partnership into European Market: Canopy Growth Corporation (TSX: WEED) (NYSE: CGC), a world-leading, diversified cannabis company and OG DNA Genetics (“DNA”), a globally recognized cannabis brand, are pleased to announce today they have signed an agreement to extend and expand upon their previously announced partnership through to 2024. With this newly signed agreement, Canopy Growth and DNA have extended their partnership beyond Canada and Jamaica and have committed to bringing DNA’s world-renowned genetics to a soon-to-be disclosed European market.
“Teaming up with DNA has proven to be a very strong and mutually beneficial partnership,” said Mark Zekulin, President and co-CEO of Canopy Growth. “Renewing our partnership for the next five years was a no-brainer for us and we look forward to introducing their high-quality DNA products to consumers around the world.”
The Cannabis Investor is a leading media outlet for Cannabis investment opportunities and breaking industry news.
Join our text message list:
USA: Text potstocks to 313131 to join
CDN: Text potstocks to 393939 to join
Join our email list here: http://eepurl.com/bUSa71
Follow The Cannabis Investor on Social Media